HI
ENTA icon

HBK Investments’s Enanta Pharmaceuticals ENTA Stock Holding History

HBK Investments’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-20,600
Closed -$2.39M – 1206
2018
Q2 		$2.39M Sell
20,600
-1,600
-7% -$160K 0.02% 440
2018
Q1 		$1.8M Buy
22,200
+18,439
+490% +$1.42M 0.01% 481
2017
Q4 		$221K Buy
+3,761
New +$188K ﹤0.01% 908

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

HBK Investments's ENTA Position: Q3 2018 in Review

HBK Investments sold out of Enanta Pharmaceuticals (ENTA) in Q3 2018, closing a stake of 20,600 shares — an estimated $2.39M sold.

HBK Investments first reported a position in ENTA in Q4 2017 and held it in 3 quarters. The position peaked at $2.39M in Q2 2018. 197 funds tracked by Wall St. Rank hold ENTA as of Q3 2018.

  • HBK Investments reported no remaining Enanta Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • HBK Investments sold 20,600 Enanta Pharmaceuticals shares in Q3 2018, an estimated $2.39M.
  • HBK Investments first reported a position in Enanta Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • HBK Investments's Enanta Pharmaceuticals position peaked at $2.39M in Q2 2018.
  • 197 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2018.

Based on HBK Investments's 13F filing for Q3 2018, filed 14 Nov 2018.